)
Edge12 Jun 2026
Set in Stone: The Story of Richemont
From a South African tobacco company to Cartier, a deep dive into how Richemont built one of the world's leading hard luxury empires.
ImmuPharma
ImmuPharma (IMM) investor relations material
ImmuPharma H2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2025 earnings summary27 May, 2026
Executive summary
Advanced lead asset P140 toward late-stage clinical readiness, with new patent filings and precision medicine approach for autoimmune diseases.
Strengthened pipeline with progress in Kapiglucagon for type 1 diabetes and anti-infective assets BioAMB and BioCIN.
Constructive regulatory engagement and ongoing discussions with potential global partners for P140.
Board and management changes, including new Chief Scientific Officer and Head of R&D.
Financial highlights
Operating loss reduced to £2.5m (2024: £2.7m); loss after tax improved to £1.8m (2024: £2.5m).
Research and development expenditure increased to £1.3m (2024: £1.2m); administrative expenses stable at £1.0m.
Finance income rose to £374k (2024: £45k); finance costs decreased to £12k (2024: £149k).
Cash and cash equivalents at year-end £1.4m (2024: £0.2m), reflecting successful equity raises.
Basic and diluted loss per share was 0.37p (2024: 0.60p); no dividend proposed.
Outlook and guidance
Focused on securing a commercial partnership for P140 in 2026.
Sufficient funding runway into 2027 following capital raises.
Strategic priority to fast-track Kapiglucagon development over the next two years.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ImmuPharma
- Accelerated funding supports P140 licensing and Kapiglucagon's rapid Type 1 diabetes development.IMM
Investor update20 Mar 2026 - P140 clinical programs advanced, fundraising bolstered liquidity, but going concern risks persist.IMMH2 202320 Feb 2026
- Losses narrowed and scientific advances achieved, but funding and going concern risks remain.IMMH2 202420 Feb 2026
- Loss increased on higher R&D, but P140 advances and new funding support future growth.IMMH1 202518 Aug 2025
- Operating loss reduced, cash position improved, and late-stage clinical pipeline advanced.IMMH1 202413 Jun 2025
Next ImmuPharma earnings date
H1 202625 Sep, 2026
ImmuPharma
Next ImmuPharma earnings date
H1 202625 Sep, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage